Cordlife Group Limited (SGX:P8A)

Market Cap	38.96M +12.6%
Revenue (ttm)	38.26M +17.2%
Net Income	-12.75M
EPS	-0.05
Shares Out	256.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	24,340
Open	0.1210
Previous Close	0.1520
Day's Range	0.1210 - 0.1210
52-Week Range	0.1210 - 0.3300
Beta	n/a
RSI	50.23
Earnings Date	May 25, 2026

About Cordlife Group

Cordlife Group Limited, an investment holding company, provides cord blood banking services in Singapore, Hong Kong, India, Malaysia, the Philippines, and internationally. It operates in two segments, Banking and Diagnostics. The Banking segment collects, processes, banks, and tests biological materials, such as cord blood, lining, and tissue samples. The Diagnostics segment offers diagnostic testing services, such as newborn genetic and metabolic screenings; pediatric vision and ear screenings; pediatric allergen test; and genetic talent test ...

• Industry: Medical - Diagnostics & Research
• Sector: Healthcare
• Founded: 2001
• Country: Singapore
• Stock Exchange: Singapore Exchange
• Ticker Symbol: P8A

Financial Performance

In 2025, Cordlife Group's revenue was 38.85 million, an increase of 40.53% compared to the previous year's 27.65 million. Losses were -12.64 million, -33.06% less than in 2024.